Showing results (11-20 of 452) with videos related to
Sort By:
Pageof 46
Urology|December 1, 1987
BCG in management of superficial bladder cancerP Guinan, R Crispen, M RubensteinUrology|March 1, 1988
Prostatic ultrasound in follow-up of prostatic diseaseP Guinan, P Ray, M RubensteinImmunological Investigations|March 1, 1993
Immunopriming of tumor infiltrating lymphocytes with neoadjuvant cyclophosphamideP Guinan, M Shaw, M RubensteinIn Vivo (Athens, Greece)|March 31, 2005
Reactive oxygen species and redox-induced programmed cell death due to MK 886: cells ("soil") "trump" agent ("seed")K M Anderson, M Rubenstein, W A Alrefai, et al.Journal of Surgical Oncology|July 1, 1996
Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude miceM Rubenstein, Y Mirochnik, P Chou, et al.International Surgery|January 1, 1993
Bilateral orchiectomy in the management of stage D-2 prostate cancerP Guinan, R Firfer, P Targonski, et al.Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2002
Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell linesM Rubenstein, Y Mirochnik, L Slobodskoy, et al.Medical Oncology (Northwood, London, England)|March 1, 1997
Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivationM Rubenstein, P Chou, Y Mirochnik, et al.Methods and Findings in Experimental and Clinical Pharmacology|March 6, 2003
Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell linesM Rubenstein, L Slobodskoy, Y Mirochnik, et al.Methods and Findings in Experimental and Clinical Pharmacology|March 26, 1999
Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotidesM Rubenstein, Y Mirochnik, P Chou, et al.Pageof 46